In contrast, presentation of HLA class II-restricted peptides and, thus, CD4+ T cell-mediated immunosurveillance, which we recently found to associate with improved outcome in ovarian cancer [30], appears to play a subsidiary role, as an indolent disease course could not be confirmed by prolonged PFS. This evidence concerns the gene CD4 and ovarian cancer.